216 related articles for article (PubMed ID: 27133878)
1. Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine.
Lundgren A; Jertborn M; Svennerholm AM
Vaccine; 2016 Jun; 34(27):3132-3140. PubMed ID: 27133878
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.
Akhtar M; Chowdhury MI; Bhuiyan TR; Kaim J; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Begum YA; Sharif MZ; Islam LN; Carlin N; Maier N; Fix A; Wierzba TF; Walker RI; Bourgeois AL; Svennerholm AM; Qadri F; Lundgren A
Vaccine; 2019 Sep; 37(37):5645-5656. PubMed ID: 30473185
[TBL] [Abstract][Full Text] [Related]
4. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactivity and avidity of antibody responses induced in humans by the oral inactivated multivalent enterotoxigenicEscherichia coli (ETEC) vaccine ETVAX.
Leach S; Lundgren A; Carlin N; Löfstrand M; Svennerholm AM
Vaccine; 2017 Jul; 35(32):3966-3973. PubMed ID: 28625524
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.
Lundgren A; Leach S; Tobias J; Carlin N; Gustafsson B; Jertborn M; Bourgeois L; Walker R; Holmgren J; Svennerholm AM
Vaccine; 2013 Feb; 31(8):1163-70. PubMed ID: 23306362
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
Qadri F; Akhtar M; Bhuiyan TR; Chowdhury MI; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Lundgren A; Wiklund G; Kaim J; Löfstrand M; Carlin N; Bourgeois AL; Maier N; Fix A; Wierzba T; Walker RI; Svennerholm AM
Lancet Infect Dis; 2020 Feb; 20(2):208-219. PubMed ID: 31757774
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX®) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
Sukwa N; Mubanga C; Hatyoka LM; Chilyabanyama ON; Chibuye M; Mundia S; Munyinda M; Kamuti E; Siyambango M; Badiozzaman S; Bosomprah S; Carlin N; Kaim J; Sjöstrand B; Simuyandi M; Chilengi R; Svennerholm AM
Vaccine; 2023 Nov; 41(46):6884-6894. PubMed ID: 37838479
[TBL] [Abstract][Full Text] [Related]
9. Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants.
Svennerholm AM; Qadri F; Lundgren A; Kaim J; Rahman Bhuiyan T; Akhtar M; Maier N; Louis Bourgeois A; Walker RI
Vaccine; 2022 Jan; 40(2):380-389. PubMed ID: 34772542
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine.
Jertborn M; Ahrén C; Svennerholm AM
Clin Diagn Lab Immunol; 2001 Mar; 8(2):424-8. PubMed ID: 11238232
[TBL] [Abstract][Full Text] [Related]
11. A Systems Biology Approach Identifies B Cell Maturation Antigen (BCMA) as a Biomarker Reflecting Oral Vaccine Induced IgA Antibody Responses in Humans.
Mottram L; Lundgren A; Svennerholm AM; Leach S
Front Immunol; 2021; 12():647873. PubMed ID: 33828557
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407.
Chakraborty S; Harro C; DeNearing B; Ram M; Feller A; Cage A; Bauers N; Bourgeois AL; Walker R; Sack DA
Clin Vaccine Immunol; 2016 Jan; 23(1):55-64. PubMed ID: 26581889
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults.
Alam MM; Aktar A; Afrin S; Rahman MA; Aktar S; Uddin T; Rahman MA; Al Mahbuba D; Chowdhury F; Khan AI; Bhuiyan TR; Begum YA; Ryan ET; Calderwood SB; Svennerholm AM; Qadri F
PLoS Negl Trop Dis; 2014 Apr; 8(4):e2822. PubMed ID: 24762744
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
[TBL] [Abstract][Full Text] [Related]
15. Mucosal Immune Responses Against an Oral Enterotoxigenic Escherichia coli Vaccine Evaluated in Clinical Trials.
Svennerholm AM; Lundgren A; Leach S; Akhtar M; Qadri F
J Infect Dis; 2021 Dec; 224(12 Suppl 2):S821-S828. PubMed ID: 34550392
[TBL] [Abstract][Full Text] [Related]
16. Intestinal immune responses in patients infected with enterotoxigenic Escherichia coli and in vaccinees.
Wennerås C; Qadri F; Bardhan PK; Sack RB; Svennerholm AM
Infect Immun; 1999 Dec; 67(12):6234-41. PubMed ID: 10569732
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant effect of enterotoxigenic
Seo H; Lu T; Mani S; Bourgeois AL; Walker R; Sack DA; Zhang W
Hum Vaccin Immunother; 2020; 16(2):419-425. PubMed ID: 31361177
[TBL] [Abstract][Full Text] [Related]
18. Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice.
Tobias J; Svennerholm AM; Carlin NI; Lebens M; Holmgren J
Vaccine; 2011 Nov; 29(48):8863-9. PubMed ID: 21983363
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.
Carpenter CM; Hall ER; Randall R; McKenzie R; Cassels F; Diaz N; Thomas N; Bedford P; Darsley M; Gewert C; Howard C; Sack RB; Sack DA; Chang HS; Gomes G; Bourgeois AL
Vaccine; 2006 May; 24(18):3709-18. PubMed ID: 16153753
[TBL] [Abstract][Full Text] [Related]
20. Oral rice-based vaccine induces passive and active immunity against enterotoxigenic E. coli-mediated diarrhea in pigs.
Takeyama N; Yuki Y; Tokuhara D; Oroku K; Mejima M; Kurokawa S; Kuroda M; Kodama T; Nagai S; Ueda S; Kiyono H
Vaccine; 2015 Sep; 33(39):5204-11. PubMed ID: 26254309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
